BioNTech to expand clinical trial programme for more anti-Omicron vaccine options
BioNTech said on Wednesday it would expand an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron coronavirus variant.
New Delhi: BioNTech said on Wednesday it would expand an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron coronavirus variant.
The addition of cohorts to a trial programme initially unveiled in January comes as global infection numbers are on the rise and protection against infection from its established Comirnaty vaccine, co-developed with Pfizer, has waned.
Thanks to 10.3 billion euros ($11.48 billion) in net income in 2021, the German biotech firm plans to spend between 1.4 billion and 1.5 billion euros on research and development this year. It also plans to buy back up to $1.5 billion worth of shares over two years and pay a special dividend of 486 million euro in total, or 2 euros per share.
It reiterated its 2022 vaccine revenue guidance of between 13 billion and 17 billion euros.
BioNTech was founded in 2008 on the understanding that every cancer patient's tumor is unique and therefore each patient's treatment should be individualized. To translate this idea into reality, BioNTech have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As BioNTech proved the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.
Next Story
